Zoetis Inc (ZTS) Shares Bought by Norinchukin Bank The

Norinchukin Bank The raised its stake in Zoetis Inc (NYSE:ZTS) by 35.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,061 shares of the company’s stock after buying an additional 24,031 shares during the period. Norinchukin Bank The’s holdings in Zoetis were worth $6,560,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ZTS. Polen Capital Management LLC purchased a new position in Zoetis in the fourth quarter valued at about $285,967,000. Bessemer Group Inc. grew its position in shares of Zoetis by 231,590.8% in the fourth quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock valued at $152,557,000 after purchasing an additional 2,116,740 shares during the last quarter. BlackRock Inc. grew its position in shares of Zoetis by 3.8% in the fourth quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock valued at $2,772,498,000 after purchasing an additional 1,394,156 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Zoetis by 111.3% in the fourth quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock valued at $123,143,000 after purchasing an additional 900,261 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in shares of Zoetis by 292.2% in the fourth quarter. Victory Capital Management Inc. now owns 1,063,051 shares of the company’s stock valued at $76,583,000 after purchasing an additional 792,000 shares during the last quarter. 94.18% of the stock is owned by institutional investors.

ZTS has been the topic of several research reports. BMO Capital Markets set a $65.00 price target on shares of Zoetis and gave the company a “hold” rating in a research report on Wednesday, October 25th. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target on the stock. in a research report on Saturday, January 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research report on Tuesday, October 24th. Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Thursday, January 4th. Finally, Cowen set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, November 17th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $79.83.

Shares of Zoetis Inc (ZTS) opened at $79.73 on Monday. Zoetis Inc has a 1 year low of $52.25 and a 1 year high of $81.40. The stock has a market cap of $38,689.28, a P/E ratio of 33.22, a P/E/G ratio of 1.80 and a beta of 1.06. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the business earned $0.47 earnings per share. Zoetis’s revenue was up 14.3% compared to the same quarter last year. analysts forecast that Zoetis Inc will post 3.02 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.63%. Zoetis’s dividend payout ratio (DPR) is currently 28.57%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://weekherald.com/2018/02/19/zoetis-inc-zts-shares-bought-by-norinchukin-bank-the.html.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Zoetis Inc (ZTS) Shares Bought by Norinchukin Bank The

Norinchukin Bank The raised its stake in Zoetis Inc (NYSE:ZTS) by 35.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,061 shares of the company’s stock after purchasing an additional 24,031 shares during the quarter. Norinchukin Bank The’s holdings in Zoetis were worth $6,560,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Zoetis in the 4th quarter valued at $108,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the last quarter. Shine Investment Advisory Services Inc. boosted its holdings in shares of Zoetis by 86.5% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after purchasing an additional 1,040 shares during the last quarter. Finally, Advisory Services Network LLC boosted its holdings in shares of Zoetis by 42.4% in the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock valued at $175,000 after purchasing an additional 721 shares during the last quarter. Institutional investors own 94.18% of the company’s stock.

A number of equities analysts have recently commented on ZTS shares. Barclays set a $77.00 target price on shares of Zoetis and gave the company a “hold” rating in a research note on Saturday. Deutsche Bank raised their target price on shares of Zoetis from $76.00 to $78.00 and gave the company a “hold” rating in a research note on Friday. Piper Jaffray Companies set a $88.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Friday. Stifel Nicolaus reissued a “buy” rating and issued a $86.00 target price (up previously from $84.00) on shares of Zoetis in a research note on Friday. Finally, Bank of America raised their target price on shares of Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $79.83.

Shares of Zoetis Inc (NYSE ZTS) opened at $79.73 on Monday. Zoetis Inc has a one year low of $52.25 and a one year high of $81.40. The stock has a market cap of $38,689.28, a price-to-earnings ratio of 33.22, a P/E/G ratio of 1.80 and a beta of 1.06. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the firm posted $0.47 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. analysts expect that Zoetis Inc will post 3.02 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.63%. The ex-dividend date is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is 28.57%.

ILLEGAL ACTIVITY NOTICE: “Zoetis Inc (ZTS) Shares Bought by Norinchukin Bank The” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://weekherald.com/2018/02/19/zoetis-inc-zts-shares-bought-by-norinchukin-bank-the.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply